Imprimis Pharmaceuticals, Inc. (NASDAQ:IMMY) tinted loss of -1.22% (-0.03 points) to US$2.42. The volume of 0.08 Million shares climbed down over an trading activity of 88.28 Million shares. EPS ratio determined by looking at last 12 month figures is -0.52. Over the same time span, the stock marked US$3.55 as its best level and the lowest price reached was US$1.35. The corporation has a market cap of US$48.21 Million.
Imprimis Pharmaceuticals, Inc. (NASDAQ:IMMY)’s earnings per share has been growing at a 13.6 percent rate over the past 5 year when average revenue increase was noted as 205.9 percent. The return on equity ratio or ROE stands at -297.9 percent while most common profitability ratio return on investment (ROI) was -35.7 percent. The company’s institutional ownership is monitored at 13.1 percent. The company’s net profit margin has achieved the current level of -35.5 percent and possesses 51.9 percent gross margin.
Teekay Corporation (NYSE:TK) is worth US$791.7 Million and has recently fallen -1.23% to US$8.04. The latest exchange of 0.38 Million shares is below its average trading activity of 790.09 Million shares. The day began at US$8.16 but the price moved to US$8.02 at one point during the trading and finally capitulating to a session high of US$8.16. The stock tapped a 52-week high of US$10.9 while the mean 12-month price target for the shares is US$7.17.
Currently, the stock carries a price to earnings ratio of 0, a price to book ratio of 0.88, and a price to sales ratio of 0.46. For the past 5 years, the company’s revenue has grown -1%, while the company’s earnings per share has grown 3.9%. With an institutional ownership near 41.3%, it carries an earnings per share ratio of -1.58.
Inside Look At Analysts Reviews
Latest analyst recommendations could offer little help to investors. The stock is a Buy among 0 brokerage firms polled by Factset Research. At present, 4 analysts recommended Holding these shares while 0 recommended sell, according to FactSet data. 1 analysts call it Underweight, while 0 think it is Overweight. Recently, investment analysts covering the stock have updated the mean rating to 3.2.